A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD

Model scores of the 29,894 trials active now.

Model score 12% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 11% of the time (407 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-12-27. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports marked serious: 39.2% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: greaterivpriordsmeffects
  Phrases that lowered it: subjectssafetyhistorychildrenkg
• Has a data monitoring committee: Yes (raises risk) · Design
• Number of arms: 4 (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 1.5% (lowers risk) · Drug's FDA history
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 2 (raises risk) · Sponsor's track record
• Disease area, neurology: No (lowers risk) · Disease area
• Design: sequential (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 6489 (raises risk) · Drug's FDA history
• Blinding: none (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pharmacokinetics of HLD200 in Children and Adolescents With ADHD NCT01907360 · started 2013 · scored riskier than 9% of active trials completed
• A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD NCT02255513 · started 2014 · scored riskier than 7% of active trials completed
• A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD) NCT01886469 · started 2013 · scored riskier than 16% of active trials completed
• Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) NCT03325894 · started 2018 · scored riskier than 39% of active trials terminated
• Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years NCT03325881 · started 2017 · scored riskier than 34% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.